Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
April 24, 2024 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
Oncology Collaboration and Licensing Agreements Report and Directory 2024: In-Depth Analysis of Stage of Development and Payment Structure of Deals
April 22, 2024 06:56 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Oncology Collaboration and Licensing...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024 07:00 ET
|
Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
April 09, 2024 08:50 ET
|
Curium
Curium proudly introduces the first commercial dose of PYLCLARI® in the Netherlands, revolutionizing prostate cancer diagnosis. This innovative 18F-PSMA PE
CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center
April 09, 2024 02:30 ET
|
Clinical Laserthermia Systems Americas, Inc.
CLS Americas received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG Thermal Therapy System accessories.
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
April 04, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024 16:30 ET
|
MacroGenics, Inc.
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...
Global Interventional Oncology Devices Market Targets Growth to $3.25 Billion by 2028
March 26, 2024 18:10 ET
|
Research and Markets
Dublin, March 26, 2024 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Expansion Driven by...
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...